Drug Importation in New Mexico: An Overview
New Mexico published the draft of its application to the U.S. Department of Health and Human Services on Oct. 29, 2020 with intent to submit to HHS by Dec. 15, 2020. Consult PSM's ongoing analysis on the right to learn more about their proposed plans.
- N.M. May Get Med Imports From Canada Under Trump Order, September 25, 2020
"An outline of the program must be submitted by Dec. 15 to the U.S. Health and Human Services Department, Morgan said, adding that the public will have a chance to comment on the program before then."
Ongoing Analysis of New Mexico's Application to HHS
The application is over 4,000 pages, so as we produce analysis or we find analysis from others, we are publishing it here. Read the October 2020 application draft, appendix, and notice of public meeting.
To get up to speed, read What is Drug Importation? A short primer and guide to keeping New Mexico residents safe and learning the myths of Canadian drug importation.
Watch our video and read the accompanying blog to hear our analysis of New Mexico's draft application.
Recent Statements Opposing Canadian Drug Importation
- American Pharmacists Association
- Canadian Pharmacists Association
- American Society of Health-System Pharmacists
- Canadian Society of Hospital Pharmacists
- National Association of Boards of Pharmacy
- Canadian Association for Pharmacy Distribution Management
Prescription Drugs in Wyoming, Evaluating State Policy Options For Lowering Costs (October 1, 2020)
The Wyoming Department of Health concluded that it is "virtually impossible to guarantee that consumers will actually see savings, particularly in the case of Canadian drug importation. Basic economics also suggests fundamental problems with this plan that make it unsustainable in the long-run."
Learn more about
Op-eds from the Experts
This editorial was published by the Institute for Policy Innovation on June 5, 2017. Its author, Dr. Merrill Matthews, is a resident scholar with the Institute for Policy Innovation, a health policy expert and contributor at Forbes.com. He also serves on the Texas Advisory Committee of the U.S. Commission on Civil Rights.
On June 1, 2017, the American Pharmacists Association (APhA), which represents 64,000 pharmacy professionals, and the National Association of Chain Drug Stores (NACDS), which represents more than 100 national and regional pharmacy chains, sent a letter to President Donald Trump urging him not to support legislation that would allow broad personal and commercial importation of non-FDA approved prescription drugs.
This editorial by Scott Bertani was published in the Washington Herald on May 7, 2017. Mr. Bertani is the Director of Policy and Community Relations for Lifelong AIDS Alliance, a nonprofit health advocacy group based in Western Washington.
This editorial by Derek Arnson appeared in the Washington Examiner on May 8, 2017. Mr. Arnson is the former Chief of Police in Nogales, Arizona.
This editorial by Wayne Winegarden, Ph.D. appeared in Forbes on April 27, 2017. Dr. Winegarden is the Managing Editor for EconoSTATS and a senior Fellow in Business and Economics at the Pacific Research Institute.
his editorial by Leona Aglukkaq appeared in the Washington Post on May 12, 2017. Leona Aglukkaq was a member of Canadian House of Commons representing the riding of Nunavut until 2015. She previously served as Canada’s minister of health from 2008-2013.
Ellen L. Carmichael’s editorial appeared in The Hayride on May 5, 2017. Carmichael formerly served as press secretary to now-Health and Human Services Secretary Tom Price, M.D. She is currently president of The Lafayette Company.
Ali Schroer wrote this editorial for the Washington Examiner on May 10, 2017.
Like millions of Americans, I take allergy medicine. A few years ago, my doctor urged me to bid farewell to my local pharmacy and instead buy my medication from an online Canadian drug store, where it was cheaper. What terrible advice! The website was counterfeit and sent me “medicine” that was anything but — causing me to get severely sick . . .
In an editorial published in the Philadelphia Inquirer, Louis J. Freeh, former director of the FBI and former federal judge, warns that allowing American citizens to purchase medicine from foreign countries puts them at risk from counterfeit drugs, would incentive criminal organizations to make counterfeit drugs, and places more stress on law enforcement efforts to combat the issue.
George Karavetsos, former head of the U.S. Food and Drug Administration’s Office of Criminal Investigations wrote this editorial for the Miami Herald on May 6, 2017.